June 16, 2020 / 11:12 AM / 23 days ago

BRIEF-Anavex Life Sciences Announces Exceeding Of Enrollment Target For Anavex2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

June 16 (Reuters) - Anavex Life Sciences Corp:

* ANAVEX LIFE SCIENCES ANNOUNCES EXCEEDING OF ENROLLMENT TARGET FOR THE ANAVEX®2-73 (BLARCAMESINE) U.S. PHASE 2 RETT SYNDROME CLINICAL TRIAL

* ANAVEX LIFE SCIENCES - EXPECTS TO ANNOUNCE TOPLINE RESULTS FROM STUDY IN 2H 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below